Drugs / LCAR-C182A cells
last change Mar 2020 re-read 2 minutes ago

LCAR-C182A cells

Cell therapy

Developed for
gastric cancer · pancreatic ductal adenocarcinoma
Investigated by
First Affiliated Hospital Xi'an Jiaotong University · Nanjing Legend Biotech Co.

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT03890198 Apr 2019 → Mar 2020 gastric cancer, pancreatic ductal adenocarcinoma First Affiliated Hospital Xi'an Jiaotong University Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LCAR-C182A cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT03890198
Modality Cell therapy “an Anti-Claudin18.2 CAR-T Cell TherapyNCT03890198